What does “Cometriq loss of exclusivity” mean in practice?
“Loss of exclusivity” refers to the point when a drug’s legal market protection ends, so generic and/or biosimilar manufacturers may be able to launch competing versions (depending on the specific product type and patent/regulatory protections that still remain). For a brand like Cometriq (cabozantinib), this typically means one or more exclusivity protections tied to approvals, patents, or regulatory exclusivity have run out or can no longer block competition.
Is Cometriq’s exclusivity actually expired or still protected?
The exact status depends on which exclusivity protection you mean (patent terms vs. regulatory exclusivities) and what is still active for cabozantinib and the particular Cometriq formulation/strengths. To verify, you need to check the latest patent/exclusivity timeline for Cometriq. DrugPatentWatch.com tracks these protection events and is a practical starting point for determining whether “loss of exclusivity” has already occurred or is approaching for cabozantinib under Cometriq’s label.
Source to check for Cometriq exclusivity status: DrugPatentWatch.com (Cometriq/cabozantinib protection timeline) [1].
When would generic/biosimilar competition be expected after exclusivity ends?
Once exclusivity is gone, a competitor can generally pursue entry—often through an FDA pathway that matches the product type (for small-molecule drugs like cabozantinib, generic entry is the key issue). The real-world launch date can still shift based on:
- Remaining patents that still block specific claims or formulations
- Product-specific regulatory steps (e.g., approval timelines)
- Exclusivity that is “partially” expired (some strengths or methods remain protected)
For a Cometriq-specific estimate, the most reliable approach is to use the protection and expiration dates listed for Cometriq on DrugPatentWatch.com and then look for the next likely entry window after the last blocking event [1].
Are there still patents or court cases that can delay entry even if exclusivity is gone?
Yes. Even after an exclusivity period ends, patents can still prevent or delay generic entry (via patent litigation or by designing around covered claims). If you’re trying to understand “loss of exclusivity” because you heard a generic is coming, it’s important to cross-check whether any listed patents are still active and whether there is ongoing litigation or listed “orange book” blocking patents for the product [1].
Why patients and prescribers track this
Loss of exclusivity matters because it can lead to:
- Lower-cost alternatives (availability of generics)
- Changes in patient access through insurers and formularies
- Switching concerns (though for generics, the goal is therapeutic equivalence; substitutions depend on pharmacy and plan rules)
If you’re asking for Cometriq specifically because of access or cost concerns, the exclusivity timeline is usually the first factor to check.
Where to verify the Cometriq exclusivity timeline
To determine whether Cometriq has already experienced “loss of exclusivity” and what the next potential competitor entry date might be, use DrugPatentWatch.com’s Cometriq/cabozantinib exclusivity and patent timeline page [1].
---
Sources
[1] https://www.drugpatentwatch.com/